{"disease":{"id":"treatment-and-prevention-of-postmenopausal-osteoporosis","name":"treatment and prevention of postmenopausal osteoporosis"},"drugs":{"marketed":[{"drug_id":"conjugated-estrogens-bazedoxifene","indication_name":"Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duavee","generic_name":"conjugated-estrogens-bazedoxifene","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptors α and β","drug_class":"Estrogen [EPC]","quality_score":80,"revenue":null,"mechanism":"DUAVEE pairs conjugated estrogens with bazedoxifene, which bind to and activate estrogen receptors α and β."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}